Syros to Host Key Opinion Leader Symposium on CDK7 Inhibition on April 24, 2019

The event will feature presentations from Dejan Juric, M.D., Medical Oncologist and Director at the Termeer Center for Targeted Therapies, Massachusetts General Hospital and Charles A. Leath, III, M.D., M.S.P.H., Professor in the Division of Gynecologic Oncology and Ellen Gregg Shook Culverhouse Chair in Gynecologic Oncology at the University of Alabama Medical Center. Additionally, members of the Syros management team will provide an overview of SY-1365, including preclinical and clinical data supporting its ongoing development in ovarian and breast cancer patients, and SY-5609, its oral selective CDK7 inhibitor, which is expected to enter a Phase 1 oncology study in early 2020.

A live webcast of the event will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals
Syros is pioneering the understanding of the non-coding regulatory region of the genome to advance a new wave of medicines that control the expression of genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is currently focused on cancer and monogenic diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia, and SY-1365, a selective CDK7 inhibitor in a Phase 1 clinical trial focused on patients with ovarian and breast cancers. Syros is also developing a deep preclinical and discovery pipeline, including SY-5609, an oral CDK7 inhibitor, as well as programs in immuno-oncology and sickle cell disease. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190417005128/en/